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Tumor necrosis factor (TNF) consists of an inflammatory cytokine essential for homeostasis and organism 
defense. Despite its physiological relevance, both increased biosynthesis and release of TNF lead to the 
exacerbation of inflammatory and oxidative responses, which are related to the pathogenesis of a host of 
diseases of an inflammatory, autoimmune and/or infectious nature. In this context, effective therapeutic 
approaches for the modulation of TNF have been the focus of research efforts. Approximately one 
million individuals worldwide have been treated with biotechnological inhibitors of this cytokine, the 
so-called anti-TNF biopharmaceuticals. However, given the high risk of infection and the limitations 
related to cost and administration routes, new therapeutic approaches aimed at biological targets that 
directly or indirectly modulate the production and/or activation of TNF appear promising alternatives 
for the discovery of new anti-inflammatory and immunomodulatory orally active drugs and are therefore 
discussed in this paper.
Uniterms: Tumor necrosis factor. TACE. p38 MAPK. NF-kB. cAMP. Phosphodiesterase. Adenosine 
receptor.
O fator de necrose tumoral (do inglês, tumor necrosis factor - TNF) consiste em uma citocina inflamatória 
essencial para a homeostase e defesa do organismo. A despeito de sua relevância fisiológica, o aumento da 
biossíntese e liberação do TNF conduzem à exacerbação das respostas inflamatória e oxidativa, as quais 
estão relacionadas à patogênese de várias doenças de natureza inflamatória, auto-imune e/ou infecciosa. 
A busca por abordagens terapêuticas eficientes na modulação do TNF tem sido alvo de diversos esforços 
de pesquisa. Aproximadamente um milhão de pessoas ao redor do mundo já foi tratado com inibidores 
biotecnológicos desta citocina, os chamados biofármacos anti-TNF. Entretanto, em face ao elevado 
risco de infecções e as limitações relacionadas ao custo e a via de administração, novas abordagens 
terapêuticas com foco em alvos que modulem, de forma direta ou indireta, a produção e/ou ativação do 
TNF surgem como alternativas promissoras para a descoberta de novos fármacos antiinflamatórios e 
imunomoduladores ativos por via oral e serão discutidas neste trabalho.
Unitermos: Fator de necrose tumoral. TACE. MAPK p38. NF-kB. AMPc. Fosfodiesterase. Receptor 
de adenosina.
INTRODUCTION
The functioning of the immune system is finely 
modulated by the activity of cytokines, pro- and anti-
inflammatory mediators (Palladino et al., 2003). Imbalan-
ces in this system can lead to the development of chronic 
inflammatory conditions, autoimmune diseases and in-
creased susceptibility and/or non-resolution of infections 
(Hanada, Yoshimura, 2002). In immune-mediated inflam-
matory disorders (IMIDs), the immune system becomes 
imbalanced  thereby preventing healing of inflammation, 
which consequently evolves and promotes tissue damage 
(Lin et al., 2008).
Therapeutic approaches currently used to treat these 
disorders focus predominantly on suppressing the produc-
tion of pro-inflammatory mediators and on the inhibition 
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of immune response triggering, by using for instance, the 
modulation of cytokine signaling pathways as a strategy 
(Hanada,Yoshimura, 2002).
The use of modulators of the production and bio-
logical activity of tumor necrosis factor alpha (TNF-α) 
in particular has been widely described and discussed in 
the literature (Lin et al., 2008), since the increased tissue 
and/or plasma concentration of this cytokine is associ-
ated with the establishment and development of several 
diseases with diverse causes. These diseases can stem 
from: (a) an autoimmune origin – e.g. Crohn’s disease, 
diabetes, psoriasis, rheumatoid arthritis and systemic lupus 
erythematosus; (b) an infectious origin – e.g. hepatitis C, 
acquired immunodeficiency syndrome (AIDS), septic 
shock, erythema nodosum leprosum; and (c) a tumor – 
e.g. multiple myeloma and ovarian cancer (Marriot et 
al., 1997; Sampaio et al., 2002; Palladino et al., 2003; 
Steinwurz, 2003; Sirohi, Powles, 2004; Paul et al., 2006; 
DasGupta et al., 2009).
Tumor necrosis factor
Tumor necrosis factor (TNF) consists of a pleiotropic 
cytokine, regulating various cellular and biological events, 
such as immune and inflammatory responses, cell differen-
tiation and proliferation, apoptosis and energy metabolism 
(Cawthorne, Sethi, 2008). TNF was originally identified 
as a substance present in the serum of animals treated with 
bacterial lipopolysaccharide (LPS), resulting in necrosis 
of tumors in vivo (Palladino et al., 2003; Paul et al., 2006).
Two types of tumor necrosis factor are currently 
known: TNF-α and TNF-� (or lymphotoxin), which pres-
ent a striking similarity in their three-dimensional struc-
tures, despite the low sequence homology (ca. 33%) found 
in the primary structure of their proteins (Gray et al., 1984; 
Pennica et al., 1984; Banner et al., 1993). The activities 
of the cytokines TNF-α and TNF-� are also very similar, 
both in vitro and in vivo, although they are antigenically 
distinct (Sack, 2002).
TNF-α is the most extensively studied cytokine 
and its main sources in vivo are activated monocytes, 
fibroblasts and endothelial cells. Macrophages, T cells, 
B lymphocytes, granulocytes, smooth muscle cells, eo-
sinophils, chondrocytes, osteoblasts, mast cells, glial cells 
and keratinocytes also produce TNF-α after stimulation 
(Mukhopadhyay et al., 2006).
LPS is the most potent stimulus triggering the bio-
synthesis of TNF-α by mononuclear phagocytes enabling 
large quantities of this cytokine to be released in infections 
by gram-negative bacteria. Other mediators induce its 
production in different cell types, including interleukin-1 
(IL-1), platelet derived growth factor (PDGF), oncostatin 
M, interferon-� (IFN-�), and the TNF-α itself, which can 
stimulate or inhibit its own synthesis, depending on the 
cell type (Mukhopadhyay et al., 2006).
The production of TNF-α begins with the adhesion 
of a ligand (which usually consists of a microbial compo-
nent) to a pattern recognition receptor (PRR) - the toll-like 
receptor (TLR), for example. This type of receptor is then 
able to recognize pathogen-associated molecular patterns 
(PAMPs), starting a cascade of signal transduction leading 
to the activation of transcription factors, such as the NF-
κB (nuclear factor kappa B) (Zuany-Amorin et al., 2002; 
Lima et al., 2006).
The NF-κB is present in the cytoplasm associ-
ated with the inhibitory protein IκBα. Activation of the 
NF-κB signaling pathway leads to phosphorylation and 
polyubiquitination of the protein IκBα and its subsequent 
degradation by the 26S proteasome. The degradation 
of this inhibitory protein releases the NF-κB dimer for 
translocation to the nucleus, inducing the transcription of 
several genes associated with the inflammatory response, 
including those encoding the cytokine TNF-α (Keifer et 
al., 2001; Suryaprasad, Prindiville, 2003).
The human TNF-α is synthesized as a polypeptide 
precursor of 233 amino acid residues attached to the cell 
membrane and is released through regiospecific proteoly-
sis between the amino acids Ala76 and Val77, producing 
the soluble form of the cytokine (Gearing et al., 1994; 
Lima et al., 2006; Mukhopadhyay et al., 2006; DasGupta 
et al., 2009). The enzyme responsible for the proteolytic 
cleavage of TNF-α anchored to the cell membrane was 
identified as a zinc-dependent metalloproteinase, denoted 
as tumor necrosis factor alpha converting enzyme (TACE) 
(Black et al., 1997; Moss et al., 1997). Cells derived from 
TACE knockout mice showed approximately 90% reduc-
tion in TNF-α release (Mohan et al., 2002).
Both forms of TNF-α, the soluble form and the 
form associated with the cell membrane, trigger biologi-
cal effects and metabolic responses, although the specific 
functions of each remain controversial (Palladino et al., 
2003; Cawthorne, Sethi, 2008; Taylor, 2010).
TNF-α exerts its multiple biological effects by 
interacting with two structural and functionally different 
receptors: the TNF receptor type I (TNF-RI, also known 
as p60, p55 or CD120a) and the TNF receptor type II 
(TNF-RII also known as p80, p75 or CD120b) (Paul et al., 
2006). Both receptors are transmembrane glycoproteins 
containing sequences of six cysteine residues that are re-
peated four times in their N-terminal extracellular domain 
(Banner et al., 1993). Although the extracellular domains 
are remarkably similar, the intracellular domains of TNF 
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receptors are significantly different, activating overlapping 
and distinct signaling pathways (Palladino et al., 2003; 
DasGupta et al., 2009).
All human nucleated cells express TNF receptors, al-
though their distribution varies according to cell type (Pal-
ladino et al., 2003). TNF-RI is constitutively expressed 
in most cells, but not in inactive T cells and erythrocytes; 
TNF-RII is expressed more often in hematopoietic and 
endothelial cells (Lima et al., 2006).
Efforts have been directed towards the elucidation of 
the specific physiological role of TNF receptors TNF-RI 
and TNF-RII, using, among other tools, knockout mice 
and monoclonal antibodies directed at the antigenically 
distinct receptors, acting as agonists. 
The use of agonists has demonstrated that the activa-
tion of TNF-RI is sufficient to mimic the biological effects 
of TNF-α in several cell compartments (Tartaglia et al., 
1993; Horssen et al., 2006; DasGupta et al., 2009). Ad-
ditionally, studies employing TNF-RI knockout mice have 
shown that these animals were resistant to LPS-induced 
liver injury, in which TNF-α plays a significant role by in-
ducing hepatic apoptosis (Shimizu et al., 2005).  The lung 
inflammatory response in TNF-RI knockout mice after 
pulmonary challenge with Micropolyspora faeni antigen 
or LPS was also significantly reduced (Smith et al., 1998).
The binding of TNF-α to the TNF-RI receptor 
triggers a cascade of events involving the activation of 
a series of serine/threonine protein kinases known as 
mitogen-activated protein kinases (MAPKs) (Paul et al., 
2006). The MAPK signaling cascade follows a sequence of 
phosphorylation and dephosphorylation reactions, starting 
with the activation of a MAPK kinase kinase (MAPKKK), 
which activates a MAPK kinase (MAPKK), which ulti-
mately leads to the activation of specific MAPKs, e.g. p38 
MAPK. The activated p38 MAPK phosphorylates other 
kinases and transcription factors, leading to the gene ex-
pression of cytokines and growth factors (Roux, Blenis, 
2004; Mutalik, Venkatesh, 2006).
Another central event in the binding of TNF-α to the 
TNF-RI is the activation of the nuclear factor NF-κB. This 
interaction activates, via the TRADD domain (tumor ne-
crosis factor receptor-1 associated death domain), the IKK 
complex (inhibitor of nuclear factor-κB kinase kinase), 
which is responsible for triggering the degradation process 
of the inhibitory protein IκBα. Once activated, the IKK 
complex phosphorylates IκBα, resulting in the release of 
NF-κB for translocation to the nucleus, and consequently, 
in the expression of genes encoding cytokines, chemokines 
and proteases (Paul et al., 2006).
Both TNF-RI and TNF-RII receptors can be cleaved 
from the cell surface by members of the matrix metallo-
proteinases family in response to inflammatory stimuli. 
The extracellular domains released through the proteolytic 
cleavage process retain the ability to bind to TNF, becom-
ing soluble TNF receptors (TNF-Rs) (Brakebusch et al., 
1994; Palladino et al., 2003).
The soluble receptors compete with membrane 
receptors for the binding of agonists TNF-α and TNF-�, 
acting as endogenous inhibitors of cytokine activity. This 
behavior allows modulation and homeostatic regulation of 
TNF activity in the body (Brakebusch et al., 1994).
TNF-α is a versatile cytokine that alters tissue remod-
eling, increases epithelial cell barrier permeability, induces 
macrophages activation, recruitment of inflammatory cells 
and expression of adhesion molecules. TNF-α also plays a 
crucial role in the development, homeostasis and adaptive 
immune response (Suryaprasad, Prindiville, 2003).
On the other hand, despite the physiological rel-
evance of this cytokine, it is known that the increase of its 
biosynthesis and release leads to exacerbation of inflam-
matory and oxidative responses, which are related to the 
pathogenesis of a wide range of diseases, e.g. rheumatoid 
arthritis, psoriasis, Crohn’s disease, erythema nodosum 
leprosum and multiple myeloma (Hashimoto, 2002; Muk-
hopadhyay et al., 2006; Lin et al., 2008).
Therapeutic strategies for TNF inhibition
The search for effective therapeutic approaches in 
the modulation of TNF-α has been the focus of  research 
efforts. Approximately one million individuals worldwide 
are either undergoing treatment or have been treated with 
TNF inhibitors available in the pharmaceutical market, 
encompassing indications that include rheumatoid arthri-
tis, psoriatic arthritis, psoriasis and inflammatory bowel 
diseases, in addition to numerous potential clinical appli-
cations which are currently in various stages of evaluation 
(Suryaprasad, Prindiville, 2003; Feldmann et al., 2005; 
Hochberg et al., 2005, Lin et al., 2008).
Several drugs commonly used as immunosuppres-
sants, e.g. cyclosporine A (1) and dexamethasone (2), 
exhibit TNF-α modulation, although their effects are 
associated with considerable toxicity. However, as the 
mechanisms that involve the production of TNF and its 
activity on cells become better understood, more spe-
cific strategies for the inhibition of this cytokine emerge. 
Examples include the development of new therapeutic 
agents and the modification of existing ones, seeking lower 
toxicity, greater potency and a larger number of clinical 
alternatives (Marriot et al., 1997).
Therapeutic approaches for TNF-α inhibition include 
neutralizing antibodies and soluble receptors of TNF-α, 
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which act as inhibitors of surface receptor occupancy; 
TACE inhibitors; and compounds structurally related to 
thalidomide (3), the first drug described as a modulator 
of the biosynthesis of this cytokine. Moreover, strategies 
for the modulation of signaling pathways involved in the 
production and biological responses promoted by TNF-α 
are also known and include some classes of therapeutic 
agents, such as protein kinase inhibitors (e.g. p38 MAPK 
inhibitors); modulators of NF-κB signaling pathway; and 
regulators of intracellular levels of cyclic adenosine-3’,5’-
monophosphate (cAMP) (DasGupta et al., 2009).
Inhibitors of TNF receptor occupancy
The introduction of biological therapies for inhibi-
tion of the pro-inflammatory cytokine TNF-α in the global 
pharmaceutical market was responsible for a revolution 
in the treatment of diseases such as rheumatoid arthritis, 
psoriasis and Crohn’s disease (Hochberg et al., 2005; 
Pappas et al., 2009).
The first two biotech drugs identified were inflix-
imab (Remicade® - Centocor/Schering-Plough) and etan-
ercept (Enbrel® - Amgen/Wyeth) (Table I). Infliximab is 
a chimeric monoclonal antibody (mAb) of approximately 
149 kDa that binds specifically to TNF-α (but not TNF-�) 
with high affinity, neutralizing its biological activity by 
inhibiting its binding to the receptors TNF-RI and TNF-
RII. Etanercept is the product of fusion of a dimeric pro-
tein of approximately 150 kDa (IgG1) with the soluble 
receptor of TNF. These features allow etanercept to bind 
to both TNF-α and TNF-� (Hochberg et al., 2005; Pappas 
et al., 2009). These biopharmaceuticals were approved 
for the treatment of rheumatoid arthritis in the late 1990s. 
Their use was later extended to include other disorders of 
autoimmune origin, including psoriatic arthritis (Pappas 
et al., 2009).
The third biotech drug described was adalimumab 
(Humira® - Abbott), a recombinant human IgG1 monoclo-
nal antibody of approximately 148 kDa specific for human 
TNF-α. Akin to infl iximab, adalimumab does not neutral-
ize TNF-�. In 2002, this biotech drug was introduced in 
the pharmaceutical market for the treatment of rheumatoid 
arthritis and its use was also recently approved for the 
treatment of other immune-inflammatory disorders (Table 
1) (Hochberg et al., 2005; Pappas et al., 2009).
The fourth biopharmaceutical identified was cer-
tolizumab pegol (Cimzia® - UCB), a humanized antibody 
fragment specific for TNF-α linked to polyethylene gly-
col. In 2008, this biological therapy was approved for the 
treatment of Crohn’s disease and, in May 2009, for the 
treatment of rheumatoid arthritis (Table I) (Tracey et al., 
2008; Pappas et al., 2009).
The use of a new biotechnology drug, golimumab 
(Simponi® - Centocor Ortho Biotech), which consists 
TABLE I - TNF inhibitors licensed for clinical use
Brand name TNF inhibitor Year Disease indicationsa Administration route
Remicade Infliximab 1998 RA, AS, PsA, psoriasis, CD, UC i.v.
Enbrel Etanercept 1999 RA, JCA, AS, PsA, psoriasis s.c.
Humira Adalimumab 2002 RA, AS, PsA, CD, psoriasis s.c.
Cimzia Certolizumab pegol 2008 CD, AR s.c.
Simponi Golimumab 2009 PsA, AR s.c.
AS: ankylosing spondylitis; CD: Crohn’s disease; JCA: juvenile chronic arthritis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; 
UC: ulcerative colitis.
a: Indications approved by United States - Food and Drug Administration (US-FDA).
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of a chimeric immunoglobulin G (G1κ mAb) specific 
for human TNF, was recently approved by the United 
States - Food and Drug Administration (US-FDA). This 
biopharmaceutical binds to both bioactive forms of TNF, 
i.e. transmembrane and soluble, thus preventing the bind-
ing of this cytokine to its receptor target. In April 2009, 
golimumab was approved for the treatment of rheumatoid 
arthritis and psoriatic arthritis (Table I) (Tracey et al., 
2008; Pappas et al., 2009).
The use of biotech drugs for the treatment of auto-
immune diseases leads to fast control of inflammation, 
resulting in an improvement in terms of function and 
structural repair of tissues. However, the benefit related to 
the use of these drugs should be evaluated by also taking 
into account the potential adverse effects associated with 
them (Suryaprasad, Prindiville, 2003).
Clinical studies have described the occurrence of in-
fections, lymphoproliferative and neurological disorders, 
autoimmune reactions and cardiac effects as recurring 
adverse events related to the continued use of biotech TNF 
modulators. The development of infection is notably the 
most common complication associated with anti-TNF-α 
biological therapy. The most commonly observed infec-
tions are in urinary and respiratory tracts (e.g. sinusitis, 
pharyngitis and bronchitis) (Suryaprasad, Prindiville, 
2003; Hochberg et al., 2005; Lin et al., 2007).
The differences in the efficacy and safety of bio-
pharmaceutical TNF-α inhibitors approved for clinical use 
remain unclear, and therefore the treatment chosen should 
be guided by expediency based on cost and availability 
(Pappas et al., 2009).
Recent studies have shown that biological anti-
TNF-α therapies are more effective when combined with 
other disease modifying anti-rheumatic drugs (DMARD), 
particularly methotrexate (4). The reports indicate that the 
treatment of rheumatoid arthritis with TNF-α biological 
inhibitors co-administered with methotrexate (4) results in 
a marked reduction of the disease symptoms and, addition-
ally, this association minimizes the rate of joint destruc-
tion more significantly compared to monotherapy with 
anti-TNF-α  biopharmaceuticals  (Caporali et al., 2009).
TACE inhibitors
From the description of therapeutic benefits related 
to anti-TNF biological therapy, concerted research effort 
has been devoted to the development of small molecules 
capable of inhibiting this cytokine through oral administra-
tion (Palladino et al., 2003; Levin et al., 2006; DasGupta 
et al., 2009).
In this context, the hypothesis that an inhibitor of 
TACE, i.e. the enzyme responsible for proteolytic cleav-
age of TNF-α anchored to the cell membrane, would be 
able to effectively treat several diseases of inflammatory 
and autoimmune origin by limiting the levels of soluble 
TNF-α, has been strengthened. Based on this objective, 
several research groups around the world are actively in-
volved in developing small molecules that inhibit TACE 
(Levin et al., 2006; Kenny, 2007; DasGupta et al., 2009).
Given the similarity between the catalytic domains 
of TACE and matrix metalloproteinases (MMPs), some 
previously identified MMP inhibitors, e.g. marimastat 
(5) and prinomastat (6), were evaluated for their potential 
inhibitory activity against TACE. Despite showing the ex-
pected biological activity, these compounds proved unsuc-
cessful in clinical trials due to adverse effects on skeletal 
muscle (DasGupta et al., 2009). Even though the exact 
mechanism responsible for the observed side effects has 
not been clearly established, some research suggests that 
the toxicity of these compounds is not linked to the inhibi-
tion of TACE, but related to their ability to inhibit MMP-1 
and/or MMP-14 (Aranapakam et al., 2003; DasGupta et 
al., 2009). Therefore, the search for new selective inhibi-
tors of TACE devoid of activity on MMPs is underway.
In an attempt to dissociate the inhibitory actions on 
MMPs and TACE, researchers at Novartis identified the 
prototypes PKF242-484 (7) and PKF241-466 (8), which 
presented pronounced anti-inflammatory activity in in 
vivo models of pulmonary inflammation, and inhibited the 
release of TNF-α in peripheral blood mononuclear acti-
vated cells with IC50 values equal to 56 nM and 141 nM, 
respectively. However, both compounds showed signifi-
cant inhibitory activity on MMPs 1, 2, 3, 9 and 13, limiting 
their development potential (Trifilieff et al., 2002).
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Some sulfonamide hydroxamates have also been de-
scribed as TACE inhibitors (DasGupta et al., 2009). Levin 
and coworkers, from Wyeth pharmaceutical industry, 
described the prototype Apratastat (9), commonly known 
as TMI-05, as a non-selective TACE inhibitor. Compound 
9 showed IC50 equal to 20 nM for the inhibition of the 
enzyme and ED50 equal to 5 mg/kg (p.o.) for the inhibi-
tion of TNF-α release stimulated by LPS in mice. This 
prototype showed significant anti-inflammatory effect in 
a model of collagen-induced arthritis in mice (Levin et al., 
2006). Although Apratastat (9) was well tolerated in phase 
I clinical trials, its development was suspended in October 
2006 due to lack of efficacy in phase II clinical trials for 
rheumatoid arthritis (Kenny, 2007).
Worth and coworkers from Roche discovered the 
ligand Ro-32-7315 (10), a potent TACE inhibitor with 
100-fold greater selectivity than most MMPs. Ro-32-7315 
(10) has shown high potency in the inhibition of TACE in 
vitro (IC50 = 5.2 nM), in the modulation of TNF-α release 
by different inflammatory cell types, and in controlling 
the onset of symptoms in animal models of inflammation. 
Compound 10 was administered to healthy human volun-
teers, but its development was eventually discontinued due 
to limited oral bioavailability (Beck et al., 2002; DasGupta 
et al., 2009).
Researchers at Bristol-Myers-Squibb have identified 
compound 11 as a selective inhibitor of TACE, with IC50 
equal to 3.7 nM for the enzyme inhibition and selectivity 
in the order of 1,000-fold greater than MMP-1, 2, 9 and 
13 (Cherney et al., 2006).
This group of scientists also designed and synthe-
sized a new series of γ-lactam hydroxamates. The designed 
compounds exhibited pronounced inhibitory activities 
in the isolated enzyme, but with low to moderate effect 
in assays using whole human blood, due to the high rate 
of binding to plasma proteins. In an attempt to increase 
the free fraction of compounds, several bioisosters with 
higher polarity were obtained and tested, most notably 
IK-682 (12). The IC50 value for 12 was equal to 1 nM in 
in vitro inhibition of the isolated enzyme and equal to 
0.35 µM in the whole human blood assay. IK-682 (12) 
showed selectivity of more than 1,000 times greater com-
pared to most MMPs, and adequate oral bioavailability 
(Duan et al., 2002; DasGupta et al., 2009).
Changes in the molecular structure of 12 resulted 
in the design of the prototype BMS-561392 (13), also de-
veloped at Bristol-Myers-Squibb. Compound 13 showed 
promising inhibitory activity in the release of soluble 
TNF-α in murine and human blood assays, as well as 
selectivity of more than 100 times in relation to MMPs. 
After its oral administration in mice, BMS-561392 (13) 
inhibited the release of soluble TNF-α induced by LPS 
with ED50 of 6 mg/kg. In phase I clinical trials, the proto-
type 13 was well tolerated by healthy human volunteers in 
a dose range of 15-530 mg, with a half-life of 3-6 hours. 
However, while BMS-561392 (13) has shown excellent 
efficacy in phase II clinical trials, these were interrupted 
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due to the observation of hepatotoxic effects (Qian et al., 
2007; DasGupta et al., 2009).
It is worth mentioning that, although the proto-
types TMI-05 (9) and BMS-561392 (13) have not been 
successful in phase II clinical trials, several compounds 
belonging to different chemical classes have been descri-
bed as selective inhibitors of TACE, some of which have 
shown promising results in preclinical tests (DasGupta et 
al., 2009).
Thalidomide and structural analogues
Thalidomide (3) ((±)2-(2,6-dioxopiperidin-3-yl)
isoindoline-1,3-dione) has several pharmacological effects 
associated with its ability to modulate immune response 
(Ng et al., 2002; Sampaio et al., 2006). The anti-inflam-
matory and immunomodulatory properties of 3 are due to 
its ability to inhibit the pro-inflammatory cytokine TNF-α. 
Thalidomide (3) increases the degradation of TNF-α 
mRNA (Moreira et al., 1993), suppressing the release of 
this cytokine from different cell types, e.g. monocytes, 
macrophages, microglia and T lymphocytes (Sampaio et 
al., 1991; Peterson et al., 1995; Deng et al., 2003; Kim 
et al., 2004; Melchert, List, 2007). TNF-α inhibition is 
largely responsible for the clinical benefits described for 
3 in patients with inflammatory and autoimmune diseases, 
who present exacerbated production of endogenous TNF-α 
(Corral, Kaplan, 1999).
Many of the pharmacological activities described 
for thalidomide (3) can be justified by its effects on the 
NF-κB signaling pathway (Sampaio et al., 2006). Com-
pound 3 blocks NF-κB activation through inhibition of the 
degradation of inhibitory protein IκBα, thus preventing the 
translocation of NF-κB to the nucleus (Mercurio, Man-
ning, 1999; Palladino et al., 2003; Sampaio et al., 2006). 
This event is due to the decrease of IKK complex catalytic 
activity, responsible for the phosphorylation step that trig-
gers the degradation of IκBα protein (Keifer et al., 2001).
The identification of the promising anti-inflammatory 
and immunomodulatory properties of 3 resulted in its ap-
proval by the US-FDA in July 1998 for the treatment of 
moderate to severe cutaneous manifestations of lepromatous 
leprosy (Matthews, McCoy, 2003; Teo et al., 2005; Lima et 
al., 2006). After approval of thalidomide (3) for the treat-
ment of erythema nodosum leprosum, a series of trials was 
initiated aimed at evaluating the therapeutic potential of 3 
in the treatment of inflammatory and autoimmune diseases 
related to increased plasma concentrations of TNF-α, such 
as rheumatoid arthritis and Crohn’s disease (Man et al., 
2003; Matthews, McCoy, 2003). More recently, in May 
2006, thalidomide (3) was approved by the FDA for the 
treatment of multiple myeloma (Melchert, List, 2007).
Despite several clinical applications assigned to 
thalidomide (3), its use is limited to the treatment of dis-
eases for which there are no alternative therapies and  is 
conditioned to the monitoring of neurological effects dur-
ing treatment and to the use of contraceptive methods in 
women (Marriott et al., 1997). With this in mind, in a bid to 
both overcome the inadequate pharmacokinetic profile of 3 
and reduce its teratogenic and neurotoxic effects, research 
efforts have been devoted to the search for new analogues 
with improved pharmacotherapeutic profile (Lima et al., 
2002; Man et al., 2003). A number of immunomodulatory 
derivatives have been reported from chemical changes in 
the structure of the starting compound, with the goal of 
generating effective alternatives for the treatment of cancer 
and immune disorders (Teo et al., 2005).
 In this context, Muller and colleagues (1999) de-
scribed a pronounced increase in the inhibitory activity of 
TNF-α production in vitro for amino-substituted analogues 
of thalidomide (3), particularly the 4-amino-phthalimidic 
derivative (14), being approximately 8,000 times more po-
tent than 3 (Figure 1). Moreover, the authors demonstrated 
that the substitution of the phthalimidic ring by a func-
tionalized isoindolinone core raised the possibility of four 
regioisomers (i.e. 16-19, Figure 1). These isoindolinone 
compounds were designed in an attempt to increase the sta-
bility and bioavailability of 3. Among them, the 4-amino-
isoindolinone analogue (16) was the only one able to sig-
nificantly inhibit the production of TNF-α (IC50 = 100 nM), 
indicating the importance of spatial orientation of the 
amino group with respect to the carbonyl of isoindolinone 
core for optimizing anti-TNF activity (Figure 1) (Muller 
et al., 1999). The derivative 16, named lenalidomide, was 
approved by the FDA in June 2006 for the treatment of 
multiple myeloma, and serves as a good example of the 
usefulness of this strategy (Melchert, List, 2007).
p38 MAPK inhibitors
The p38 mitogen-activated protein kinase (p38 
MAPK) has received extraordinary attention from the 
pharmaceutical industry and medicinal chemists since it 
FIGURE 1 - Thalidomide (3) and analogues (14-19) and the 
inhibition of TNF-α production induced by LPS in human 
mononuclear cells (Muller et al., 1999). 
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was first described in 1993. It is considered a promising 
target for therapeutic intervention (Montalban et al., 2008).
This premise is based on the fact that the cytokines 
TNF-α and interleukin-1� (IL-1�) play an important role in 
the pathogenesis of many inflammatory diseases, and the 
signal transduction pathway that results in the production 
of these cytokines is partially regulated by p38 MAPK 
(Montalban et al., 2008). The p38 MAPK is activated 
from an extracellular stimulus, thus phosphorylating and 
activating other kinases and transcription factors, leading 
to the stabilization of TNF-α and IL-1� mRNA and to the 
increase of the gene expression of these cytokines (Pal-
ladino et al., 2003).
The relevance of p38 MAPK in inflammatory 
responses has been shown in a number of studies using 
chemical inhibitors. Another study using p38α knockout 
macrophages demonstrated that deficiency of this protein 
kinase causes a significant inhibition in the production of 
TNF-α, IL-12, and IL-18 induced by LPS, highlighting the 
role of p38α in the activation of these inflammatory cells 
(Kang et al., 2008).
The description of an initial series of imidazo-pyri-
dine derivatives was an important tool for elucidating the 
role of p38 MAPK in inflammation. The first pyridinylimi-
dazol described was SKF-86002 (20), with potent activity 
in modulating the cytokine production stimulated by LPS 
(Kumar et al., 2003).
In 1993, the structure-activity relationship for anti-
inflammatory effects of the congener series of pyridinyli-
midazoles was described by exploring the inhibition of 
enzymes 5-lipoxygenase/cyclooxygenase (5-LO/COX) 
and the modulation of cytokine biosynthesis as poten-
tial mechanisms of action. Subsequently, the compound 
SB-203580 (21) and other 2,4,5-triaryl-imidazoles were 
synthesized and used as pharmacological tools in the se-
arch for the molecular target involved in the modulation 
of cytokine biosynthesis. This study finally allowed the 
correlation of the desired biological activity with p38 
MAPK inhibition, thereby characterizing the potential 
of this protein kinase as an anti-inflammatory target (Bo-
ehm et al., 1996; Kumar et al., 2003). However, further 
experiments revealed the hepatotoxic and carcinogenic 
profile of SB-203580 (21) as a result of potent inhibition 
of cytochrome P450 (Zhang et al., 2007).
Drawing on the description of p38 MAPK as a pro-
mising therapeutic target, new inhibitors were designed 
and obtained using molecular modification strategies, e.g. 
RWJ-68 354 (22), BIRB-796 (23), SCIO-469 (24), VX-
702 (25) and VX-745 (26) (Henry et al., 1998; Liverton 
et al., 1999; Kim et al., 2008). Most of the compounds 
available act as competitive inhibitors with BIRB-796 (23) 
constituting one of the few examples of known allosteric 
inhibitors (Montalban et al., 2008).
The varied safety profiles and different structural 
classes that encompass the p38 MAPK inhibitors sug-
gest that the possible toxicity is probably related to the 
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molecules that inhibit IKK-�, some at the stage of phase 
I or phase II clinical trials for the treatment of different 
diseases, predominantly cancer (Edwards et al., 2009). 
Studies have shown that IKK-� deficient cells are defective 
in activation of NF-κB in response to TNF-α or IL-1 (Li 
et al., 1999), blocking systemic inflammation in a model 
of intestinal injury (Knowlton, 2006).
Among the available IKK-� inhibitors, some 
compounds should be highlighted, including TCPA-1 
(32, GlaxoSmithKline), ML120B (33, Millennium Phar-
maceuticals), SC-514 (34, Pfizer), BMS-345541 (35, 
Bristol-Myers Squibb) and BAY-117085 (36, Bayer), 
with proven efficacy and potency in in vitro assays and 
pronounced anti-inflammatory activity in vivo (Edwards 
et al., 2009).
TCPA-1 (32), a selective inhibitor of IKK-� 
(IC50 = 17.9 nM) described by the pharmaceutical industry 
GlaxoSmithKline, was found to decrease the release of 
cytokines TNF-α, IL-6 and IL-8 induced by LPS and sig-
nificantly reduced the severity of inflammation associated 
with a murine model of collagen-induced arthritis when 
therapeutically administered at a dose of 20 mg/kg (i.p.) 
(Podolin et al., 2005).
Compounds ML120B (33) and SC-514 (34) are se-
lective, reversible and ATP-competitive IKK-� inhibitors, 
blocking different cellular responses regulated by NF-kB, 
which are involved in inflammation and the tissue injury 
structural characteristics of these compounds and not to 
their mechanism of action. However, despite all research 
efforts, the employment of a small molecule that acts as an 
inhibitor of this protein kinase as a drug remains elusive 
(Montalban et al., 2008).
Modulators of NF-kB signaling pathway
The transcription factor NF-kB plays a central role 
in inflammation and immune response, acting as a me-
diator both in TNF-α biosynthesis and in the biological 
response mediated by the binding of TNF-α to its target 
receptor (Hanada, Yoshimura, 2002; Lima et al., 2006; 
Paul et al., 2006). For this reason, the identification of 
small molecules that inhibit the NF-kB signaling pathway 
has emerged as a promising therapeutic approach for the 
treatment of inflammatory and autoimmune diseases (Ha-
nada, Yoshimura, 2002; Palladino et al., 2003).
In addition to thalidomide (3) and its structural ana-
logues (Figure 2), several classes of compounds have been 
described as inhibitors of NF-kB activation, including 
natural products, e.g. capsaicin (29) and parthenolide (30); 
non-steroidal anti-inflammatory drugs; glucocorticoids; 
IKK inhibitors; and proteasome inhibitors (Palladino et 
al., 2003; De-Blanco et al., 2007).
A broad array of natural products appears to interfere 
with NF-kB activation and subsequent gene transcription. 
Capsaicin (29), for example, reduces the degradation of 
the inhibitory protein IkB-α through activation of vanilloid 
receptors and modification of the redox state of cells. The 
gene transcriptions dependent on NF-kB are modulated 
by antioxidants, e.g. vitamin E (31), and stimulated by 
reactive oxygen species (Palladino et al., 2003).
Some sesquiterpene lactones found in plants are also 
able to modulate this signaling pathway. Parthenolide (30), 
extracted from the medicinal herb Tanacetum parthenium, 
binds directly and inhibits IKK-�, i.e. the catalytic subunit 
of the IKK complex responsible for degradation of IkB-α 
in response to different pro-inflammatory stimuli (Pal-
ladino et al., 2003).
The inhibition of IKK-� is a strategy of increasing 
interest to researchers in academia and in the pharmaceuti-
cal industry, resulting in the description of several small 
FIGURE 2 - Thalidomide (3) and analogues (14, 27 and 28) and the inhibition of NF-kB translocation to the nucleus in HeLa cell 
line (human epithelial cells from cervical carcinoma) (De-Blanco et al., 2007).
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process characteristic of rheumatoid arthritis (Kishore et 
al., 2003; Wen et al., 2006).
Prototype BMS-345541 (35) (Bristol-Myers 
Squibb) on the other hand, is an allosteric inhibitor of 
both catalytic subunits of IKK complex, with IC50 equal to 
0.3 µM for IKK-� and 4 µM for IKK-α. This compound 
inhibits the release of cytokines TNF-α, IL-1�, IL-6 and 
IL-8 in vitro, and presents a suitable pharmacokinetic 
profile in mice, being able to modulate the in vivo produc-
tion of TNF-α induced by LPS after oral administration 
(Burke et al., 2003).
BAY-117085 (36), identified by researchers at 
Bayer, inhibits the phosphorylation of inhibitory protein 
IkB-α in a selective and irreversible manner, producing 
an in vivo anti-inflammatory effect in murine models of 
carrageenan-induced paw edema and arthritis induced by 
adjuvant (Pierce et al., 1997).
Additionally, proteasome inhibitors, which affect 
signaling via NF-kB, have also been identified as promis-
ing disease modifying anti-inflammatory agents (Edwards 
et al., 2009).
The ubiquitin-proteasome system (UPS) is respon-
sible for the proteolytic degradation of most cellular pro-
teins, such as the inhibitory protein IkB-α, thus playing 
a relevant role in the modulation of NF-kB activity. The 
26S proteasome consists of an ATP-dependent proteolytic 
complex, constituted by a proteolytic core called 20S 
proteasome, associated with two 19S regulatory subunits 
(Adams, 2003; Voorhees, Orlowski, 2006).
Compounds described as proteasome inhibitors 
present anti-tumor activity in vitro and in vivo, and bort-
ezomib (37, Millennium Pharmaceuticals) was the first 
to be evaluated in clinical trials, demonstrating efficacy 
in the treatment of multiple myeloma and non-Hodgkin 
lymphoma (Voorhees, Orlowski, 2006).
Some natural products have also been identified as 
inhibitors of this proteolytic complex, e.g. lactacystin (38) 
and epoxomicin (39), which irreversibly inhibit the 20S 
proteasome (Voorhees, Orlowski, 2006).
Conversely, the synthetic tripeptide aldehyde MG-
132 (40) binds and inhibits the active site of the 20S pro-
teasome through the formation of a reversible hemiacetal, 
resulting in promising anti-inflammatory effects in asthma 
and chronic obstructive pulmonary disease (COPD). 
Studies have demonstrated the ability of 40 to reduce the 
inflammation associated with allergic stimulus, the func-
tion of eosinophils, and, therefore, the release of mediators 
responsible for tissue injury by these cells (Voorhees, 
Orlowski, 2006; Edwards et al., 2009).
Modulators of intracellular cAMP levels
3’,5’-cyclic adenosine monophosphate (cAMP) and 
3’,5’-cyclic guanosine monophosphate (cGMP) are second 
messengers generated by the action of adenylate cyclase 
and guanylate cyclase, respectively, which are involved 
in a vast array of cellular responses to different stimuli 
(Figure 3) (Lima et al., 2002; Chung, 2006).
These second messengers activate specific intracel-
lular proteins, such as protein kinase A and protein kinase 
G, which phosphorylate proteins that regulate different 
physiological processes, e.g. transcription factors and ion 
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channels, resulting in diverse biological effects. In the 
inflammatory response, the activation of protein kinase 
A prevents transcriptional factors, such as NF-κB, from 
promoting the expression of genes encoding cytokines. 
Thus, agents that induce higher levels of cAMP, either 
by stimulating its formation or by preventing its degrada-
tion, inhibit pro-inflammatory cytokines, e.g. TNF-α and 
IL-1�, resulting in an immunosuppressive effect (Figure 
4) (Chung, 2006).
In this context, new classes of drugs able to modulate 
intracellular levels of cAMP emerge as useful therapeutic 
strategies, such as phosphodiesterase inhibitors and modu-
lators of the adenosine system (Lipworth, 2005; Chung, 
2006; Jacobson, Gao, 2006).
· Phosphodiesterase inhibitors
Phosphodiesterases are a group of eleven families 
of enzymes (PDEs 1-11) responsible for the hydrolysis of 
cyclic nucleotides cAMP and cGMP, generating the respec-
tive 5'-monophosphates. These families of phosphodiestera-
ses are expressed differently in different tissues and diverge 
in terms of amino acid sequence, substrate specificity, 
sensitivity to certain inhibitors, biochemical parameters and 
modulation of enzyme activity. For the last decade, studies 
involving the control of cAMP and cGMP levels through 
the activity of PDEs have intensified, with their relevance 
evidenced by the number of clinical trials of selective PDE 
inhibitors for various inflammatory diseases, e.g. asthma 
and COPD (Lipworth, 2005; Chung, 2006).
Phosphodiesterase 4 (PDE4) in particular plays a 
central role in the immune cells involved in inflammatory 
response and is predominantly expressed in mast cells, 
eosinophils, neutrophils, T lymphocytes, macrophages 
and some structural cells, e.g. epithelial cells and neurons. 
The PDE4 family, specific for cAMP hydrolysis, is divided 
into four subtypes, PDE4A, PDE4B, PDE4C and PDE4D 
(Houslay et al., 2005; Chung, 2006).
Rolipram (41), developed by Schering AG phar-
maceutical industry, is a highly selective first generation 
PDE4 inhibitor used as a pharmacological tool for inves-
tigating the role of this enzyme. This compound has anti-
inflammatory and immunomodulatory effects, and inhibits 
the release of cytokines from activated T lymphocytes, 
basophils, monocytes, macrophages and airway epithelial 
cells (Chung, 2006).
In a bid to reduce the adverse effects associated with 
this class of drugs, the occurrence of nausea and vomiting in 
particular, several second generation PDE4 inhibitors were 
described, such as Cilomilast (42, GlaxoSmithKline) and 
Roflumilast (43, Altana), which reached the stage of phase 
III clinical trials (Houslay et al., 2005; Lipworth, 2005).
Recent studies describe the involvement of PDE4 
subtypes in the onset of the different biological effects of 
these inhibitors. The PDE4B appears to mediate most of 
the anti-inflammatory effects, while PDE4D is responsible 
for the adverse effects reported, mainly emesis (Lipworth, 
FIGURE 3 - Biosynthesis of cAMP by adenylate cyclase and its hydrolysis to adenosine-5’-monophosphate (AMP) by the action 
of phosphodiesterase 4 (PDE4).
FIGURE 4 - Biology of cAMP and its role in the modulation of 
inflammatory response.
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2005). Researchers have described that PDE4D knockout 
mice showed no adverse effects, while studies with 
PDE4B knockout mice confirmed that this PDE4 subtype 
is essential for biosynthesis of TNF-α induced by LPS 
in vivo (Boswell-Smith et al., 2006). PDE4B knockout 
animals have shown almost complete suppression of 
this cytokine (Yamamoto et al., 2007), suggesting that a 
PDE4B selective inhibitor could potentially be an effective 
anti-inflammatory agent which does not induce emesis 
(Boswell-Smith et al., 2006). 
Cilomilast (42) is ten times more selective for 
PDE4D than for other isoenzymes (i.e., PDE4A, PDE4B 
and PDE4C), while Roflumilast (43) shows no selectivity 
for the different isoforms of PDE4. The selectivity of 42 
for PDE4D, responsible for the induction of nausea in 
patients, explains why this compound is less tolerated than 
Roflumilast (43) (Lipworth, 2005).
The search for PDE4 inhibitors without emetic 
effects led to the discovery of compounds with lower 
activity against the PDE4D isoform, such as the indole 
derivative AWD-12-281 (44, GlaxoSmithKline), the inda-
zole derivative Tofimilast (45, Pfizer), and the benzofuran 
derivative Lirimilast (46, Bayer) (Houslay et al., 2005).
· Modulators of the adenosine system
Adenosine is an endogenous purine nucleoside 
(Figure 4) released by various cells, which regulates physi-
ological processes by activating specific receptors. There 
are four known subtypes of adenosine receptors, named A1, 
A2A, A2B and A3, all coupled to the G protein, related to a 
variety of signal transduction pathways (Haskó, Cronstein, 
2004; Zhang et al., 2005).
The release of adenosine is increased in response to 
tissue injury. An accentuated production of this nucleo-
side is described in several pathological conditions, e.g. 
inflammation, hypoxia and ischemia. Adenosine can be 
metabolized by action of the enzyme adenosine deami-
nase, leading to inosine; or can be converted intracellularly 
to the nucleotide adenosine monophosphate (AMP) by the 
action of the enzyme adenosine kinase (Fredholm et al., 
2001; Zhang et al., 2005).
Each adenosine receptor subtype has its particulari-
ties with regard to signaling and final physiological effects. 
In the classical description, the signaling triggered by 
these receptors is mediated by inhibition or stimulation of 
adenylate cyclase, although there are current indications 
of the relevance of other mediators and enzymes, e.g. 
calcium, phospholipase C and mitogen-activated protein 
kinases (MAPKs) (Jacobson, Gao, 2006).
The A2A and A2B receptors, coupled to stimulatory 
G protein, activate adenylate cyclase and increase intra-
cellular cAMP (Figure 4). On the other hand, the A1 and 
A3 receptors coupled to inhibitory G protein, reduce the 
release of intracellular cAMP. Thus, several studies have 
shown that agonists of A2A and A2B receptors could act as 
anti-inflammatory agents, and this activity was attributed, 
at least in part, to reduced release of TNF-α. However, 
recent studies have indicated that activation of A2B recep-
tors is also associated with the release of several allergic 
and pro-inflammatory mediators, whereas activation of 
the A2A receptor present in most immune cells including 
lymphocytes, monocytes, macrophages and dendritic 
cells, appears to effectively alleviate inflammation and 
reperfusion injury in different tissues (Zhang et al., 2005; 
Jacobson, Gao, 2006).
In this context, several A2A receptor agonists have 
been reported in the literature as drug candidates for the 
treatment of inflammatory diseases. For example, the 
A2A receptor agonist BMS-068645 (ATL-146e) (47), 
developed by Bristol-Myers Squibb, has a promising anti-
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inflammatory profile associated with the modulation of 
TNF-α and interferon gamma (INF-g) release by activated 
T lymphocytes, limiting the activation of T cells and mac-
rophages in inflamed tissues. Conversely, the prototype 
CGS21680 (48), produced by Novartis, has pronounced 
anti-inflammatory activity in different murine models of 
allergic asthma, emerging as an alternative therapy for the 
treatment of this disease (Jacobson, Gao, 2006).
Dual inhibitors of TNF-α and PDE4
Aiming to optimize TNF-α modulator activity, dif-
ferent research groups have explored the ability of thalido-
mide (3) and derivatives to directly inhibit the biosynthesis 
of this cytokine associated with the strategy of indirect 
modulation, which is based on increasing the intracel-
lular cAMP concentration (Lima et al., 2006). Agents 
that induce higher levels of cAMP, either by stimulating 
its production or preventing its degradation, cause an 
inhibition of pro-inflammatory cytokines such as TNF-α, 
IL-1� and INF-g, reducing the recruitment and activation 
of inflammatory cells resulting in an immunosuppressive 
effect (Marriott et al., 1997; Gallant et al., 2008).
Muller and colleagues described phthalimidic ana-
logues of thalidomide (3) containing the dialcoxy-phenyl 
core, a pharmacophoric group present in PDE4 inhibitors, 
e.g. rolipram (41), cilomilast (42) and roflumilast (43), 
aiming to obtain dual inhibitors of TNF-α and PDE4. The 
new phthalimidic dialcoxy-phenyl derivatives (49-52, 
Figure 5) effectively reduced TNF-α release in peripheral 
blood mononuclear cells stimulated by LPS, and signifi-
cantly inhibited the enzymatic activity of PDE4, acting 
through a different mechanism of action to that described 
for prototype 3 (Muller et al., 1998; Lima et al., 2006).
The Laboratório de Avaliação e Síntese de Sub-
stâncias Bioativas (LASSBio®), of the Federal University 
of Rio de Janeiro, has also made its contribution to the 
research and development of dual inhibitors of TNF-α 
and PDE4. In this lab, a congener series of N-phenyl sul-
fonamide phthalimidic derivatives designed by molecular 
hybridization of the prototype thalidomide (3) with the 
selective PDE-4 inhibitor N-(2,3-dihydro-1H-1-indenil)-
3,4-dimethoxy-benzene-sulfonamide (53) was synthesized 
(Figure 6) (Montana et al., 1998; Lima et al., 2002; Lima 
et al., 2006).
FIGURE 5 - Inhibitory activity of thalidomide (3) and analogues (49-52) in the TNF-α release in peripheral blood mononuclear 
cells stimulated by LPS and in the enzymatic activity of PDE4 (Muller et al., 1998).
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The determination of the anti-inflammatory proper-
ties of the new N-phenyl sulfonamide phthalimidic deriva-
tives (54-58) was carried out according to the pharmaco-
logical protocol for acute lung inflammation induced by 
LPS inhalation in mice. The results indicated  good overall 
anti-inflammatory activity for this new series of deriva-
tives when administered intraperitoneally, especially the 
compound LASSBio-468 (58), which showed an ED50 of 
2.5 mg/kg in this assay (Lima et al., 2002).
The identified prototype (58) also reduced TNF-α 
mRNA levels analyzed by reverse transcription polymerase 
chain reaction (RT-PCR) in mice peritoneal macrophages 
stimulated by LPS (Alexandre-Moreira et al., 2005); and 
significantly inhibited the NF-κB activation induced by 
TNF-α at concentrations greater than 257 μM (100 mg/
mL) in U937 cell line, comprising monocytic cells extracted 
from human histiocytic lymphoma (Abreu, 2007).
In addition to the anti-TNF-α activity previously 
described, LASSBio-468 (58) showed the ability to inhibit 
PDE-4 isoform in vitro (IC50 = 80 μM) and was also found 
to be inactive against the other isoforms of this enzyme 
(PDE1, PDE2, PDE3 and PDE5) at concentrations greater 
than 300 μM (Alexandre-Moreira et al., 2005).
This prototype has a pronounced anti-inflammatory 
and immunomodulatory profile, possibly resulting from 
a complex mechanism of action involving, besides the 
elevation of cAMP levels in immunocompetent cells, other 
independent biological properties, including the ability to 
reduce the stability of TNF-α mRNA (Alexandre-Moreira 
et al., 2005; Lima et al., 2006).
FINAL CONSIDERATIONS
The anti-TNF biological therapies currently avail-
able in the pharmaceutical market have led to a revolution 
in the treatment of chronic degenerative inflammatory 
diseases, characterizing this therapeutic approach as ef-
fective in improving the quality of life of a significant 
number of patients. Worldwide, approximately one million 
individuals are either undergoing treatment or have been 
treated with TNF inhibitors, comprising indications that 
include rheumatoid arthritis, psoriatic arthritis, psoriasis 
and inflammatory bowel diseases. In addition, numerous 
potential clinical applications are still undergoing evalu-
ation. However, these therapies have risks and limitations 
associated with their continued employment including 
their high cost, the inconvenience of exclusive administra-
tion in hospitals and the incidence of significant adverse 
effects such as a high susceptibility to infections.
In this context, the discovery of small molecules able 
to modulate TNF activities, preferentially when adminis-
tered orally, could represent an alternative to biopharma-
ceutical agents. To this end, different mechanisms of TNF 
modulation have been characterized, e.g. the inhibition 
of TACE; the inhibition of protein kinases, such as p38 
MAPK; the modulation of NF-κB signaling pathway; and 
the increase in intracellular cAMP levels through the use 
of phosphodiesterase inhibitors and/or adenosine system 
modulators; offering a wide range of possible targets for 
the design and development of new drug candidates with 
better pharmacotherapeutic profiles.
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